References
[1] Fahim, S., Jain, V., Victor, G., Pierscianowski, T. (2006). Piperacillin tazobactam–induced drug hypersensitivity syndrome. Cutis, 2006, 77: 353-357.
[2] Cacoub, P., Musette, P., Descamps, V., Meyer, O., Speirs, C., Finzi, L., et al. (2001). The DRESS syndrome: a literature review. Am J Med., 2001, 124(7): 588-597.
[3] Cabanas, R., Calderon, O., Ramirez, E., Fiandor, A., Prior, N., Caballero, T., et al. (2014). Piperacillin-induced DRESS: dis-tinguishing features observed in a clinical and allergy study of 8 patients. J Investig Allergol Clin Immunol., 2014, 24(6): 425-430.
[4] Girelli, F., Bernardi, S., Gardelli, L., Bassi, B., Parente, G., Dubini, A., et al. (2013). A new case of DRESS syndrome induced by sulfaslalazine and triggered by amoxicillin. Case Rep Rheumatol, 2013: 409152.
[5] Sharpe, A., Mourad, B. M., Hardwick, J., Reilly, T., Dweck, E., Bondarsky, E. (2019). Oxacillin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Am J Case Rep., 2019, 20: 345-348.
[6] Artuković, M., Kuštelega, J., Lugović-Mihić, L. (2010). DRESS syndrome with mild manifestations as a diagnostic and therapeutic problem: case report. Acta Clin Croatica, 49(4): 479-484.
[7] Jhang, J. F., Kuo, H. C. (2017). Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. Ci Ji Yi Xue Za Zhi, 2017, 29(3): 131-7.
[8] Ronald, A. (2003). The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon, 2003, 49(2): 71-82.
[9] Cunha, B. A. (1989). Nitrofurantoin: an update. Obstet Gynecol Surv., 1989, 44(5): 399-406.
[10] Guay, D. R. (2001). An update on the role of nitrofurans in the management of urinary tract infections. Drugs, 2001, 61(3): 353-64.
[11] Leao, R. N., Barreto, P., Leao, R. R., et al. (2013). Nitrofurantoin: Cause of dress syndrome. BMJ Case Rep., 2013; 2013. pii: bcr2013008991.
[12] Travis, W. D., Colby, T. V., Koss, M. N., et al. (2002). Non-neoplastic disorders of the lower respiratory tract. Atlas of nontumor pathology. Washington, The American Registry of Pathology, 2002, 2: 327.
[13] Mendez, J. L., Nadrous, H. F., Hartman, T. E., Ryu, J. H. (2005). Chronic Nitrofurantoin-induced lung disease. Mayo Clin Proc, 2005, 80: 1298.
[14] Holmberg, L., Boman, G. (1981). Pulmonary reactions to Nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis., 1981, 62: 180.
[15] Sovijärvi, A. R., Lemola, M., Stenius, B., Idänpään-Heikkilä, J. (1977). Nitrofurantoin-induced acute, sub acute and chronic pulmonary reactions. Scand J Respir Dis., 1977, 58: 41.
[16] Santos, J. M., Batech, M., Pelter, M. A., Deamer, R. L. (2016). Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc., 2016, 64: 798.
[17] Kabbara, W. K., Kordahi, M. C. (2015). Nitrofurantoin-induced pulmonary toxicity: A case report and review of the literature. J Infect Public Health, 2015, 8: 309.
[18] Huttner, A., Verhaegh, E. M., Harbarth, S., et al. (2015). Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015, 70: 2456.
[19] Jick, S. S., Jick, H., Walker, A. M., Hunter, J. R. (1989). Hospitalizations for pulmonary reactions following Nitrofurantoin use. Chest, 1989, 96: 512.
[20] Velema, M. S., Voerman, H. J. (2009). Dress syndrome caused by Nitrofurantoin. Neth J Med., 2009, 67(4): 147-9.
[21] Munoz-Davila, M. J. (2014). Role of old antibiotics in the era of antibiotic resistance. Highlighted Nitrofurantoin for the treatment of lower urinary tract infections. Antibiotics, 2014, 3(1): 39-48.
[22] Marshall, A. D., Dempsey, O. J. (2013). Is “Nitrofurantoin lung” on the increase? Br Med J., 2013, 346: f3897.
[23] Brumfitt, W., Hamilton-Miller, J. M. (1998). Efficacy and safety profile of long-term Nitrofurantoin in urinary infections: 18 years’ experience. J Antimicrob Chemother, 1998, 42(3): 363-71.
[24] Holmberg, L., Boman, G., Bottiger, L. E., et al. (1980). Adverse reactions to Nitrofurantoin. An analysis of 921 reports. Am J Med., 1980, 69(5): 733-8.
[25] Huttner, A., Verhaegh, E. M., Harbarth, S., et al. (2015). Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015, 70(9): 2456-64.
[26] Broes, M. J., Roelofs, B. F., Mudde, A. H., et al. (2012). Pulmonary toxicity resulting from the use of Nitrofurantoin. Ned Tisdschr Geneeskd, 2012, 156(44): A4990.
[27] Mendez, J. L., Nadrous, H. F., Hartman, T. E., et al. (2005). Chronic Nitrofurantoin-induced lung disease. Mayo Clin Proc, 2005, 80(10): 1298-302.
[28] Taweesedt, P. T., Nordstrom, C. W., Stoeckel J., Dumic. (2019). Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. Biomed Res Int., 2019, 5: 1-10
[29] Díaz-Mancebo, R., Costero-Fernandez, O., Vega-Cabrera, C., OleaTejero, T., Yebenes, L., Picazo, M. L., et al. (2012). Dress syndrome and acute tubulo interstitial nephritis after treatment with vancomycin and beta-lactams. Case report and literature review. Nefrología (English Edition), 2012, 32(5): 685-687.
[30] Forster, C. J., Cohee, B. M., Wood-Morris, R. N., Hartzell, J. D. (2009). Nitrofurantoin-induced systemic inflammatory response syndrome. Am J Med Sci., 2009, 338: 338-340.
[31] Gandotra, S. D., Smotrys, M. A., Patel, D. B., Chadha, A. (2017). Systemic inflammatory response syndrome (SIRS) and a left bundle branch block (LBBB) due to nitrofurantoin. BMJ Case Rep., 2017, 2017: bcr2016218127.
[32] Gohar, A., Abdallah, M., Elsayed, S., Pierobon, J. (2020). Systemic inflammatory response syndrome due to nitrofurantoin use. Am J Ther. Published online January 13, 2020. doi:10.1097/ MJT.0000000000001110.
[33] Smith, A. A., LeDoux, E. (2011). A convincing case of nitrofurantoin induced systemic inflammation response syndrome. J Gen Int Med., 2011, 26: S376.
[34] Bäck, O., Liden, S., Ahlstedt, S. (1977). Adverse reactions to nitrofurantoin in relation to cellular and humoral immune responses. Clin Exp Immunol., 1977, 28: 400-406.